HFR-1 Table 1Demographics, baseline Barrett’s baseline information and outcome of all patients who have completed the Cytosponge ® procedure. * 2 patients still awaiting endoscopic assessment. NDBE: Non-Dysplastic Barrett’s Oesophagus, INDEF: Indefinite for dysplasia, LGD: Low-Grade Dysplasia, IMC: intramucosal adenocarcinoma TFF3: - Atypia: - P53: - TFF3: + Atypia: - P53: - TFF3: -/+ Atypia: + P53: - TFF3: + Atypia: + P53: + Number of patients 14 26 12 4 M:F 12 : 2 20 : 6 11 : 1 4 : 0 Median maximal BE length (cm) 2.5 5 5 6 Triage decision Repeat Cytosponge®/endoscopy within 24 months Endoscopy in 12 months Endoscopy within 3 months Endoscopy within 3 months Endoscopy and histology findings - - NDBE: 5 ATYPIA: 1 INDEF: 2 LGD: 2 NDBE: 1 LGD: 2 IMC: 1 ConclusionsThe Cytosponge® has proved to be an acceptable non-endoscopic tool for patients with BE under surveillance where endoscopy is not possible. Preliminary data are promising to detect dysplasia and triage patients to endoscopy early. Further large scale, longitudinal follow-up is needed.
Cytosponge as a risk stratification tool in patients overdue barrett’s surveillance due to Covid-19